Pricing and reimbursement, US, UK, France, Germany, Spain, Italy, Japan, Clinical guidelines, Health technology assessments, HTA, ASCO, NCCN, ESMO, Japanese Lung Cancer Society, National Medical Society, AIFA, CEPS, CMS, DGFPS, G-BA, INEK, IQWIG, MHLW, NICE, SMC, TC, UVEF

The scope of each report

Comprehensive secondary research, experienced based insight and validation by payers and Key Opinion Leaders (KOLs) across markets underpins PRMA Insights: The Roadmap to Pricing and Reimbursement Success:

Reporting of the regulatory indications and key supporting data for the major targeted therapies.

The current pricing and reimbursement landscape for each disease in the Top 7 major pharmaceutical markets:

Spain

Italy

France

Japan

Germany

Reviews of the clinical guidelines for each disease area including:

ASCO

Japanese Lung Cancer Society

NCCN

National Medical Societies

ESMO

The comprehensive review and assessment of all pricing and reimbursement and HTA decisions for targeted therapies and all relevant chemotherapeutic backbones across all lines of therapy.

The assessments of Health Technology Assessments (HTA) and pricing and reimbursement decisions recently made in each disease area by the following bodies:

AIFA

G-BA

NICE

CEPS

INEK

SMC

CMS

IQWIG

DGFPS

MHLW

UVEF

To find out more or register your disease area interest, click here

Query Form

click to expand

Fill in the fields below and press submit. A member of our team
will respond shortly.